Japan's conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA.
Cancer Cell
; 39(9): 1165-1166, 2021 09 13.
Article
in En
| MEDLINE
| ID: mdl-34358449
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Approval
/
Legislation, Drug
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Humans
Country/Region as subject:
America do norte
/
Asia
Language:
En
Journal:
Cancer Cell
Journal subject:
NEOPLASIAS
Year:
2021
Document type:
Article
Country of publication:
Estados Unidos